Previous Article | Next Article 
Journal of Virology, September 2000, p. 8335-8342, Vol. 74, No. 18
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Inherent Instability of Poliovirus Genomes Containing Two
Internal Ribosome Entry Site (IRES) Elements Supports a Role for
the IRES in Encapsidation
Lisa K.
Johansen and
Casey D.
Morrow*
Department of Microbiology, University of
Alabama at Birmingham, Birmingham, Alabama 35294
Received 24 February 2000/Accepted 20 June 2000
 |
ABSTRACT |
Previous studies have described poliovirus genomes in which the
internal ribosome entry (IRES) for encephalomyocarditis virus (EMCV) is positioned between the P1 and P2-P3 open reading frames of
the poliovirus genome. Although these dicistronic poliovirus genomes were replication competent, most exhibited evidence of genetic
instability, and the EMCV IRES was deleted upon serial passage. One
possible reason for instability of the genome is that the dicistronic
genome was at least 108% larger than the wild-type poliovirus genome,
which could reduce the efficiency of encapsidation. To address this
possibility, we have constructed dicistronic poliovirus replicons by
substituting the EMCV IRES and the gene encoding luciferase in place of
the poliovirus P1 region; the resulting dicistronic replicons are
smaller than the wild-type poliovirus genome. One dicistronic genome
was constructed in which the poliovirus 5' nontranslated region was
fused to the gene encoding luciferase, followed by the
complete EMCV IRES fused to the P2-P3 region of the poliovirus genome
(PV-Luc-EMCV). A second dicistronic genome, EMCV-Luc-PV, was
constructed with the first 108 nucleotides of the poliovirus genome
fused to the EMCV IRES, followed by the gene encoding luciferase and
the poliovirus IRES fused to the remaining P2-P3 region of the
poliovirus genome. Both dicistronic replicons expressed abundant
luciferase following transfection of in vitro-transcribed RNA into HeLa
cells at 30, 33, or 37°C. The luciferase activity detected from
PV-Luc-EMCV increased rapidly during the first 4 h following
transfection and then plateaued, peaking after approximately 24 h.
In contrast, the luciferase activity detected from EMCV-Luc-PV
increased for approximately 12 h following transfection; by
24 h posttransfection, the overall levels of luciferase activity
were similar to that of PV-Luc-EMCV. To analyze encapsidation of the
dicistronic replicons, we used a system in which the capsid protein
(P1) is provided in trans from a recombinant vaccinia virus
(VV-P1). The PV-Luc-EMCV replicon was unstable upon serial
passage in the presence of VV-P1, with deletions of the EMCV IRES
region detected even during the initial transfection at 37°C.
Following serial passage in the presence of VV-P1 at 33 or 30°C, we
detected deleted genomes in which the luciferase gene was fused with
the P2-P3 genes of the poliovirus genome so as to maintain the
translational reading frame. In contrast, the EMCV-Luc-PV replicon was
genetically stable during passage with VV-P1 at 33 or 30°C. The
encapsidation of EMCV-Luc-PV was compared to that of monocistronic
replicons encoding luciferase with either a poliovirus or EMCV IRES.
Analysis of the encapsidated replicons after four serial passages with
VV-P1 revealed that the dicistronic replicon was encapsidated more
efficiently than the monocistronic replicon with the EMCV IRES but less
efficiently than the monicistronic replicon with the poliovirus
IRES. The results of this study suggest a genetic predisposition
for picornavirus genomes to contain a single IRES region and are
discussed with respect to a role of the IRES in encapsidation.
 |
INTRODUCTION |
Poliovirus (PV) is a small,
nonenveloped RNA virus of the Picornaviridae family. The
poliovirus genome is a single-stranded RNA approximately 7,440 nucleotides in length. The plus-strand, genomic RNA functions as mRNA
for viral protein expression and serves as a template for
negative-strand RNA synthesis. The genomic RNA is initially translated
as a long single polyprotein, which has been subdivided into three
regions: the P1 region encodes the structural capsid proteins, while
the P2 and P3 regions encode nonstructural proteins (18, 30,
31). The individual proteins are released from the polyprotein by
virus-encoded protease 2Apro, which cleaves the P1 from the
P2-P3 region in an autocatalytic reaction (32). The protease
3Cpro processes the remaining P2-P3 region proteins
(16, 34). P1 is processed in trans by a
3Cpro fusion with the viral RNA-dependent RNA polymerase
(3Dpol), which is referred to as 3CDpro
(8).
One of the first steps in a PV infection is translation of the genomic
RNA. The initiation of translation occurs in a cap-independent manner
in the 5' nontranslated region (5'NTR), at a region referred to as the
internal ribosome entry site (IRES) (12, 13, 25-27). The
IRES region contains a high degree of RNA secondary structure encompassing nucleotides 134 to 556 of the PV 5'NTR (10, 19, 22). All members of the family Picornaviridae contain
IRES elements in the 5'NTR. Encephalomyocarditis virus (EMCV) contains
an IRES element encompassing approximately 500 nucleotides (nucleotides 335 to 836) (14). Although the EMCV IRES performs the same
function as the PV IRES, there is little sequence or secondary
structure homology (33). This fact has been exploited in
previous studies to construct PV genomes that contain both the PV and
EMCV IRES elements (dicistronic genomes). Dicistronic genomes were
constructed to encode the EMCV IRES between the P1 and P2-P3 regions of
PV (1, 7, 20, 21). Previous studies by Molla et al.
(20, 21) and Paul et al. (24) have described the
construction and characterization of dicistronic PVs in which the EMCV
IRES was inserted into the PV infectious clone. Constructs which
contained the EMCV IRES between the P1 and P2-P3 junction or the 2A-2B
junction generated viable viruses which retained the EMCV IRES,
although it was not clear for how many serial passages. Alexander et
al. (1) characterized a dicistronic PV which contained the
EMCV IRES positioned between the PV IRES and P1. Although this virus retained the EMCV IRES for a single passage, analysis after five serial
passages revealed that the genome had lost the EMCV IRES (1). One possibility for genetic instability with the
dicistronic genomes could be that all were larger than the wild-type PV
genome, which might result in constraints in encapsidation and
facilitate deletion upon serial passage.
To explore the reasons for the instability of the dicistronic genomes,
we have used a system in which the P1 coding region of PV can be
removed and replaced with a foreign gene (replicon) (6).
Removal of the P1 gene allows for the insertion of approximately 2.5 kb
into the PV genome without increasing the overall genome size. Using
this system, we have constructed dicistronic genomes containing the
IRES elements from both PV and EMCV and the gene encoding luciferase.
One replicon contains the PV IRES followed by the luciferase gene, EMCV
IRES, and the remaining P2-P3 region genes (PV-Luc-EMCV); this genome
was similar to the previously described dicistronic PV genome (20,
21). The second replicon (EMCV-Luc-PV), which contains the IRES
elements in the reciprocal order, has not been previously described.
Encapsidation and serial passage of the dicistronic replicons in the
presence of recombinant vaccinia virus VV-P1 revealed a difference in
genetic stability between the two genomes. The results of this study
are discussed with respect to an as yet unappreciated role for the IRES
in enhancing encapsidation.
 |
MATERIALS AND METHODS |
Unless otherwise noted, all chemicals and reagents were
purchased from Sigma Chemical Company. The tissue culture media and supplements, as well as synthetic DNA primers, restriction enzymes, Taq polymerase, Superscript preamplification system, and
reagents for PCR, were purchased from Gibco BRL. The luciferase assay
kits and pGEM-T Easy vector cloning kits were purchased from Promega (Madison, Wis.). Tri-reagent was purchased from Molecular Research Center, Inc. QIAquick gel extraction kits were purchased from Qiagen.
MAXIscript T7 kits and RPA III kits were purchased from Ambion.
Construction of dicistronic genomes.
Plasmids pT7-IC-Gag1
(6, 28), pT7-IC-CEAsig
(3), pGEM-Luc (Promega),
and pCITE-4a(+) (Novagen) were used for construction of the dicistronic
genome pPV-Luc-EMCV. An EcoRI-to-SnaBI fragment of pT7-IC-CEAsig
was cloned into pT7-IC-Gag1, creating the
pT7-XhoI-SnaBI cloning vector. The luciferase gene from pGEM-Luc was
amplified by PCR, creating an XhoI site 5' to the start
codon and an HpaI site 3' of the stop codon (primers,
5'-CTCGAGGAAGACGCCAAAAACATAAG-3' and
5'-GTTAACCAATTTGGACTTTCCGCC-3'). The EMCV IRES was amplified from pCITE-4a(+) and encoded both XhoI and SnaBI
sites at the 5' end of the fragment and an HpaI site at the
3' end, following the AUG start codon (primers,
5'-CTCGAGAAGCTTTACGTAGGTTATTTTCCACCATATTGC-3' and
5'-GTTAACGGCCATATTATCATCGTG-3'). The EMCV IRES fragment
(XhoI to HpaI) was cloned into the
XhoI-SnaBI region of pT7-XhoI-SnaBI. After
confirmation, the resulting plasmid was digested with XhoI and SnaBI and the luciferase fragment (XhoI to
HpaI) was subcloned, resulting in plasmid pPV-Luc-EMCV. The
plasmid sequence was confirmed by DNA sequencing.
For construction of the second dicistronic genome, we used plasmids
pEMCV-Luc and pPV-Luc (15; see Fig. 4). A PCR fragment containing the
T7 promoter, first 108 nucleotides of PV, EMCV IRES, and luciferase
gene from pEMCV-Luc was amplified, creating a SacI site 3'
of the luciferase stop codon (primers,
5'-CCAGTGAATTCCTAATACGACTCACTATAGGTTAAAACAGC-3' and
5'-GAGCTCTTACAATTTGGACTTTCCGCCC-3'). The PV IRES from
pPV-Luc was amplified with a SacI site at the 5' of the
region and a SnaBI site at the 3' end (primers,
5'-GAGCTCGACGCACAAAACCAAGTTCAATAG-3' and
5'-TACGTACATTATGATACAATTGTCTG-3'). These two fragments,
along with a SnaBI-to-EcoRI fragment from
pPV-Luc, which contains the remaining PV genome and plasmid, were
subcloned together in a three-way ligation. The resulting plasmid,
pEMCV-Luc-PV, was characterized by restriction enzyme analysis, and the
sequence was confirmed by DNA sequencing.
In vitro transcription and transfections.
Plasmids
pPV-Luc-EMCV and pEMCV-Luc-PV were linearized with the
restriction enzyme SalI. RNA was generated by in vitro
transcription reactions using T7 RNA polymerase as previously described
(6). Relative levels of in vitro-transcribed RNA were
determined by spot densitometry using the Alphaimager 3.2 program. For
transfection, HeLa H1 cells were first infected with recombinant
vaccinia virus VV-P1 (4, 28) at 10 PFU/cell for 3 h.
Equal amounts of RNA were transfected by the DEAE-dextran method as
previously described (6). Transfection and subsequent
incubations were all carried out at 37, 33, or 30°C.
Encapsidation of replicons.
The encapsidation and serial
passage of poliovirus replicons using VV-P1 have been described
previously (4, 28). Briefly, in vitro-transcribed RNA was
transfected into HeLa H1 cells previously infected for 3 h with
VV-P1 as described above. The cultures were harvested 48 h after
transfection by three freeze-thaw cycles, overlaid on a 30% sucrose
cushion (30% sucrose, 30 mM Tris [pH 8.0], 0.1 mM NaCl), and
centrifuged in an SW41 rotor (Beckman) at 40,000 rpm (4°C) overnight.
Supernatants were discarded; the pellets were resuspended in serum-free
Dulbecco modified Eagle medium and used for serial passage.
For serial passage of the encapsidated replicons, HeLa H1 cells were
infected with 10 PFU of VV-P1 per cell (at the designated
temperature).
After 3 h, the cells were infected with the supernatant
containing
the encapsidated replicons. Cultures were harvested
48 h
postinfection by three successive freeze-thaw cycles and
clarified by
centrifugation at 14,000 rpm for 20 min. These supernatants
were stored
at

70°C or used for additional
passages.
Luciferase assay.
For analysis of luciferase protein
expression, HeLa H1 cells were transfected or infected and harvested at
the designated times by being washed once with phosphate-buffered
saline (PBS) and then resuspended in 1 ml of PBS. The cells were
pelleted for 6 min at 14,000 rpm, and the PBS was removed; 100 µl of
1× lysis buffer (Promega) was used to resuspend the cell pellet. The
samples were assayed for light detection using a luminometer (Moonlight 2010; Analytical Luminescence Laboratories) (29). The raw
relative light unit (RLU) data were used to calculate the total RLU in a sample. All infections for the determination of luciferase activity were carried out overnight (15 h) at 37°C unless otherwise specified. The luciferase activities presented were representative of three different experiments.
RNA isolation and RT-PCR analysis.
Tri-reagent-LS was used
to isolate total RNA from HeLa H1 cells infected overnight with
passages of encapsidated replicon according to the manufacturer's
instructions as modified for the Superscript kit (Gibco BRL). The total
RNA was resuspended in 100 µl of RNase-free water, and 5 µl was
used in the reverse transcription (RT) reaction. Two minus-sense
primers, spanning PV nucleotides 3068 to 3086 (primer c;
5'-TCGAATACCAACATACGG-3') or nucleotides 3481 to 3495 (primer d; 5'-CTACTCCACATGACG-3'), were used. The two
positive-sense primers used for PCR spanned nucleotides 1541 to 1560 of
luciferase (primer b; 5'-CGACGCGGGCGTGGCAGGTC-3') or nucleotides 1 to 30 of PV (primer a;
5'-TTAAAACAGCTCTGGGGTTGTACCCACCCC-3'). The minus-sense and
positive-sense primers were used in all possible combinations in the
PCRs. The RT-PCR products were gel isolated, purified using a QIAquick
gel extraction kit, and cloned into the pGEM-T Easy vector system.
Individual colonies from the ligations were grown; plasmid DNA was
extracted and used for DNA sequencing.
Comparison of the encapsidation of dicistronic and monocistronic
replicons.
The monocistronic replicons PV-Luc and EMCV-Luc are
described elsewhere (15; see Fig. 4). EMCV-Luc contains the nucleotides corresponding to the EMCV IRES substituted for the PV IRES
(13). EMCV-Luc, PV-Luc, and EMCV-Luc-PV were encapsidated at
33°C in the presence of VV-P1. After four serial passages under
identical conditions at 33°C, the amount of encapsidated replicons
was estimated by luciferase expression. The amount of luciferase
detected following the four serial passages was divided by the amount
obtained using the starting inoculum to determine the fold increase of
replicon obtained following serial passage.
 |
RESULTS |
Construction of dicistronic replicon genomes.
In this study,
we have constructed two dicistronic replicons that encode the
luciferase gene in place of the PV P1 gene (Fig. 1). The first replicon, PV-Luc-EMCV,
contains the complete 5'NTR of PV followed by the gene encoding
luciferase. The stop codon of the carboxy terminus of luciferase is
immediately followed by the EMCV IRES (nucleotides 335 to 836 of the
EMCV genome). The EMCV IRES is fused to nucleotide 2956 of the PV
genome so that the AUG codon contributed by the EMCV IRES is followed,
in frame, by the codons from the remaining VP1 gene. Note that the EMCV
IRES does not contain the upstream poly(C) tract as found in the
previously described dicistronic genomes (20, 21). Translation promoted by the EMCV IRES in this construct would be
predicted to include the region encoding the final 143 amino acids of
the VP1 protein, followed by the intact P2-P3 proteins of PV.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Construction of dicistronic replicons PV-Luc-EMCV and
EMCV-Luc-PV. (A) PV-Luc-EMCV. The gene encoding luciferase was cloned
following the complete PV 5'NTR. Following the termination codon for
luciferase, the IRES from EMCV was fused to nucleotide (nuc.) 2956 of
the PV genome, maintaining the translational reading frame of the
VP1-P2-P3 region of the genome. The plasmid containing the dicistronic
genome (pPV-Luc-EMCV) was linearized with SalI, followed by
in vitro transcription to generate the replicon RNA used for
transfection. The predicted genome size is 7,381 nucleotides. (B)
EMCV-Luc-PV. The EMCV IRES (502 nucleotides) was cloned 3' to the first
108 nucleotides of the PV genome. The gene encoding luciferase was
cloned after the EMCV IRES. Following the termination codon for
luciferase, the 637-nucleotide region of the PV 5'NTR was cloned in
frame with the VP1-P2-P3 region. The plasmid containing the replicon,
pEMCV-Luc-PV, was linearized with SalI prior to in vitro
transcription to generate the replicon RNA.
|
|
In the second dicistronic genome constructed, the IRES of EMCV was
positioned 5' to the luciferase gene and the IRES from
the PV genome
was 3' to the luciferase gene. This dicistronic
genome contained the
first 108 nucleotides of PV at the extreme
5' end of the genome, as
this region has been shown to be important
for viral replication
(
2). For the PV IRES region, nucleotides
109 to 745 of the
PV 5'NTR were fused in frame with the PV VP1
gene at nucleotide 2956. As with the previous dicistronic genome,
the PV IRES would promote
synthesis of a truncated VP1 protein
followed by the complete P2-P3
region proteins. To our knowledge,
this arrangement of IRES elements
has not been previously described
in a complete PV genome. Note that
the two dicistronic genomes
are identical in size and approximately 60 nucleotides smaller
than the complete PV
genome.
Analysis of luciferase expression from dicistronic replicons.
Luciferase protein expression was first analyzed from the two
dicistronic replicons following RNA transfection. In preliminary experiments, we established that the increase in luciferase expression directly correlates with the capacity of the genome to undergo self-amplification following transfection into cells. Genomes in which
the open reading frame was disrupted so that a truncated 3Dpol was expressed did not produce increased levels of
luciferase after the first 2 h following transfection (data not
shown). Thus, following transfection, both translation and replication
of the dicistronic genomes can be ascertained by measurement of
luciferase. Three different temperatures, 37, 33, and 30°C, were used
for the transfections. HeLa cells were first infected with VV-P1, and
3 h later in vitro-transcribed replicon RNA was transfected into
the cells. At 2, 4, 6, 11, and 24 h after transfection, luciferase activity was determined (Fig. 2). We
chose to analyze translation and replication in the presence of VV-P1
since subsequent experiments would use these experimental
conditions for encapsidation. Similar expression profiles were
generated for each replicon at the different temperatures in the
absence of VV-P1 (data not shown).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 2.
Kinetics of luciferase gene expression from dicistronic
replicons PV-Luc-EMCV and EMCV-Luc-PV. Equivalent amounts of in
vitro-transcribed RNA from pPV-Luc-EMCV (A) or pEMCV-Luc-PV (B) were
transfected into HeLa cells previously infected with VV-P1 for 3 h. The cells were then incubated at the designated temperatures for the
specified times. Cell lysates were prepared and analyzed for luciferase
expression. Total RLU was plotted versus the same time posttransfection
for each temperature.
|
|
Expression of luciferase from the PV-Luc-EMCV replicon increased
rapidly during the first 4 h, and then leveled off, reaching
a
peak at 24 h. The kinetics of luciferase expression correlated
with that observed for production of viral proteins from previously
described dicistronic PV genomes (
20,
21). The kinetics for
expression of luciferase from the EMCV-Luc-PV replicon was slightly
different from the PV-Luc-EMCV replicon. Luciferase activity increased
in a linear fashion during the first 12 h following transfection
and then plateaued, reaching a level similar to that for the replicon
PV-Luc-EMCV at approximately 24
h.
Encapsidation of dicistronic replicons.
In previous studies,
we have demonstrated that replicons can be encapsidated by serial
passage in the presence of a recombinant vaccinia virus, VV-P1, which
provides capsids proteins in trans. To monitor
encapsidation, luciferase activity was analyzed following a single
round of encapsidation (transfection) and after two, four, and eight
serial passages in the presence of VV-P1. Analysis of luciferase
expression from the replicon PV-Luc-EMCV following transfection at
37°C revealed luciferase activity from the transfection and through
two serial passages ranging from 100- to 1,000-fold over background
(Table 1). By serial passage 4, in the
presence of VV-P1, we did not detect any luciferase activity over the
background levels. Furthermore, no 3Dpol-related proteins
(i.e., 3CD) were detected following metabolic labeling and
immunoprecipitation. Additional analysis using RT-PCR (see below)
confirmed the absence of replicon genomes. In contrast, luciferase
activity was detected following transfection and all subsequent serial
passages at 33 or 30°C for PV-Luc-EMCV.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Analysis of the genetic stability of PV-Luc-EMCV
following encapsidation and serial passage at three
different temperatures
|
|
RT-PCR was used to analyze the genome stability of PV-Luc-EMCV during
the transfection and serial passages. PCR primers were
chosen to
amplify critical regions of the dicistronic replicon
spanning the 5'NTR
of PV, the luciferase gene, the EMCV IRES,
and the VP1 and 2A genes of
PV. RT-PCR from PV-Luc-EMCV encapsidated
at 37°C revealed the
presence of smaller than predicted amplified
DNA even during the first
round of encapsidation (Table
1 and
Fig.
3). Similarly, RT-PCR analysis of
PV-Luc-EMCV passaged at
33°C revealed amplified DNA smaller than
expected. In contrast
to the samples passaged at 37°C, at passage 4, abundant levels
of luciferase activity were still detected from the
33°C-passaged
replicons; the levels at passages 4 and 8 at 33°C
were 10
4- to 10
6-fold over background (Table
1). RT-PCR of PV-Luc-EMCV following
transfection and serial passage at
30°C revealed that during transfection
and through passage 4, DNA was
amplified at the appropriate size
for the intact PV
IRES-luciferase-EMCV IRES genes. However, analysis
of the passage 4 samples revealed amplified DNA that was full
length or smaller than
expected; by passage 8, only the truncated
DNA was amplified by RT-PCR.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 3.
Analysis of PV-Luc-EMCV genomes following
transfection and serial passage. (A) Schematic of the starting
dicistronic genome. The boxed numbers refer to nucleotides in the PV
genome. The underlined numbers refer to positions in the gene encoding
luciferase. Nucleotides 335 to 836 of the EMCV genome correspond to the
IRES [without poly(C) tract]. Primers used for RT-PCR (a to d) are
marked by arrows and described in Materials and Methods. (B) Schematic
of the major genomes recovered by RT-PCR from transfections and serial
passages. The RT-PCR products recovered from transfections (Trfxn) or
serial passages in the presence of VV-P1 (p2, p4, and p8) were cloned
and sequenced. The major deleted genomes recovered at all temperatures
consisted of a fusion between the luciferase (nucleotide
1798) and VP1 (nucleotide 3034) genes to maintain the translational
reading frame. The original dicistronic genome was also recovered from
early passages at lower temperatures. (C) Nucleotide and
predicted amino acid sequences of the luciferase-VP1 gene fusion. The
entire EMCV IRES was deleted from the original dicistronic construct,
along with 78 nucleotides of the PV VP1 coding region (from nucleotides
2956 to 3033). The PV nucleotides are boxed, and the luciferase
nucleotides are underlined. The first two nucleotides of the luciferase
stop codon are in bold; the last two luciferase nucleotides and the
first two PV nucleotides are identical. Note that although a Y-G
amino acid dipeptide is present a few amino acids from the 3' end
of the luciferase gene, the P4 amino acid is F rather than the L
required for optimal 2Apro cleavage (9).
|
|
To further characterize the nature of the deletions of the replicon
genome, we cloned the RT-PCR DNA and determined the DNA
sequence. The
major deleted genome observed consisted of an in-frame
fusion between
nucleotide 1798 of the luciferase gene and nucleotide
3034 of the PV
VP1 gene (Fig.
3C). This deletion was found after
several independent
transfections and serial passage trials at
37, 33, and 30°C. The
resulting gene fusion reestablished the
translational reading frame
between luciferase and the VP1-P2-P3
region of the PV genome. The
entire EMCV IRES element was deleted.
The fusion genome was stable for
at least 18 additional serial
passages at 33°C. Other deletion
products were found which also
contained fusions between the luciferase
gene and VP1 (luciferase
nucleotide 1795 and nucleotide 3040 of PV or
nucleotide 1453 of
luciferase and 2955 of PV [this fusion also
contained 13 random
nucleotides between the two sites]). These two
fusion products
were recovered from individual RT-PCR clones and were
each detected
only once. Thus, most (98%) of the deleted genomes
cloned contained
the 1798-3034 in-frame deletion. At present, it is
not clear why
we did not detect similar deleted genomes from the
passages at
37°C.
In contrast, the dicistronic replicon EMCV-Luc-PV appeared stable at
all three temperatures examined for serial passage in
the presence of
VV-P1 (Table
2). Luciferase activity was
detected
following transfection and up to two serial passages at
37°C (at
least 100-fold over background). However, by passage 4 at
37°C,
we did not detect luciferase activity above background. We
confirmed
that there were no replicon genomes in these cultures by
using
metabolic labeling and immunoprecipitation for 3CD. The
dicistronic
replicon, EMCV-Luc-PV, appeared stable following
transfection
and serial passage at 33 or 30°C. Analysis of
these encapsidated
replicons following eight serial passages revealed
abundant luciferase
activity at least 100-fold over background.
Furthermore, using
RT-PCR, we did not amplify smaller DNA products for
the EMCV IRES-luciferase-PV
IRES genes, indications of gene deletion.
DNA sequence of the
RT-PCR product confirmed the presence of the
starting dicistronic
genome (data not shown).
Comparison of the encapsidation of dicistronic EMCV-Luc-PV and
monocistronic replicons.
To further characterize the dicistronic
replicon EMCV-Luc-PV, we compared the encapsidation of EMCV-Luc-PV with
that of two previously constructed monocistronic replicons (Fig.
4A). In one replicon, EMCV-Luc, the EMCV
IRES is substituted for the PV IRES; this replicon contains the first
108 nucleotides of the PV genome fused with the EMCV IRES followed by
the gene encoding luciferase (15). The second replicon,
PV-Luc, contains the intact PV 5'NTR fused to luciferase. All three
replicons produce luciferase and have genomes that are smaller than the
wild-type PV genome. We compared the relative encapsidation efficiency
of each of these replicons following four serial passages. In
preliminary studies, we found that the amount of luciferase activity
detected following infection from the individual replicons reflected
the amount of encapsidated replicon (29). The luciferase
activity obtained following the fourth serial passage was compared with
the luciferase activity used to initiate the serial passages (pass 1).
Passage of all replicons was carried out under identical conditions at 33°C. The results are represented as fold increase over the starting levels of encapsidated replicon (Fig. 4B). The monocistronic
replicon, PV-Luc, was most efficiently amplified after four
serial passages, with an approximately 1,500-fold increase over the
starting amount of encapsidated replicon. In contrast, the
monocistronic replicon with the EMCV IRES substituted for the PV IRES
(EMCV-Luc) was amplified only 200-fold following the four serial
passages, a result consistent with our previous studies
(15). Surprisingly, we found that the dicistronic replicon
EMCV-Luc-PV was amplified approximately 1,000-fold over the
starting amount, clearly greater than that observed for the
monocistronic EMCV-Luc replicon but less than that found for
PV-Luc.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
Encapsidation of the dicistronic EMCV-Luc-PV compared
with that of monocistronic replicons. (A) Schematic of the three
replicons used to compare encapsidation efficiency. Encapsidated
dicistronic replicon EMCV-Luc-PV was obtained from serial passage in
the presence of VV-P1 at 33°C. Two additional monocistronic
encapsidated replicons were also used; PV-Luc encodes the luciferase
gene substituted for the P1 gene of PV, and EMCV-Luc contains the first
108 nucleotides (nuc.) of the PV 5'NTR fused with the EMCV IRES
followed by the luciferase gene. Both monocistronic replicons were
encapsidated and propagated at 33°C. (B) The passages were initiated
using replicons at approximately 0.5 infectious unit per cell.
Luciferase activity was determined and designated pass 1. Three
additional serial passages of the replicons were performed under
identical conditions. Equal amounts of each passage were used to infect
cells, and luciferase activity was determined. The fold increase in
luciferase expression over starting amounts was determined for each
replicon.
|
|
 |
DISCUSSION |
In this study, we investigated the genetic stability and
encapsidation of dicistronic PV replicons. We constructed two replicons which contained the luciferase reporter gene and the IRES regions from
both PV and EMCV. The replicon PV-Luc-EMCV was genetically unstable at
three different temperatures used for encapsidation. A replicon genome
was identified from these passages which contained a fusion between the
luciferase gene and the remaining PV polyprotein. The replicon
containing this deletion was stable and could be passaged following
growth at 33°C. In contrast, the replicon EMCV-Luc-PV was stable
following propagation at 33 and 30°C. Comparison of the encapsidation
efficiency between a monocistronic replicon, which contains the EMCV
IRES substituted for the poliovirus IRES, with the dicistronic replicon
EMCV-Luc-PV revealed that the dicistronic replicon was more efficiently
encapsidated following serial passage in the presence of VV-P1.
Previous studies have described the characterization of dicistronic PV
genomes containing the EMCV IRES positioned between the P1 and P2-P3
open reading frames or the 2A and 2B proteins. Although both genomes
produced infectious viruses upon transfection, it was not clear if
these viruses were genetically stable following serial passages
(20, 21, 24). Genomes with the EMCV IRES positioned between
the PV IRES and P1 were unstable after five serial passages, resulting
in a deletion of the EMCV IRES (1). Similarly, a dicistronic
genome with the gene encoding chloramphenicol acetyltransferase and the
EMCV IRES was unstable following five serial passages (1).
The reason for the genetic instability was not clear, since previous
studies established that little sequence homology exists between the
EMCV and PV IRES elements, making it unlikely that there would be
genetic recombination between the two (11, 13). One
possibility for the instability of these dicistronic genomes was they
were all approximately 108 to 117% larger than the wild-type PV genome
(1, 20, 21, 24). It was not possible, though, to address the
question of whether the genome size had any relationship to the
subsequent genetic instability because all of the PV genes present were
required for infectivity. Replicons do not have this limitation, as the capsids are provided in trans. The dicistronic replicons
then were constructed so that the overall size was similar to that of
the PV genome; thus, genome size would not be the major reason for the
instability of these dicistronic genomes. However, the results of our
analysis of PV-Luc-EMCV demonstrated genome instability, indicating a
genetic predisposition for PV to contain a single IRES element.
Analysis of the replicon gene deletion found during the propagation of
PV-Luc-EMCV provides some insights into the constraints that the PV
genome has overcome in order to maintain a monocistronic genome. The
major deleted genome recovered contained a fusion between the
luciferase gene and the VP1 gene, so that the translational reading
frame was maintained. The reason for the fusion at nucleotides 3034 of
the PV genome is not evident. Based on what is known about PV
recombination, we would speculate that the recombination occurred
during minus-strand synthesis (17). It is possible that the
78 nucleotides of VP1 not found in the deleted genome might have been
undergoing translation and thus blocked for access by the replicase
synthesizing minus strands. In other words, the presence of ribosomes
near the first 78 nucleotides of the VP1 gene might have disrupted the
PV RNA-dependent RNA polymerase synthesizing a minus strand from the
opposite direction, thus facilitating a translocation of the replicase
to the luciferase gene. The fact that the complete luciferase gene was
recovered is somewhat perplexing. One explanation might be that the
polymerase had landed many times within the EMCV IRES, followed by
continued RNA transcription to make a complete minus strand. Plus
strand from this minus-strand RNA might not be infectious because it would lack a complete IRES for translation initiation of the P2 and P3
genes and/or the translational reading frame would not be conserved
between the luciferase and remaining P2-P3 region. Thus, the first site
where the PV replicase might land during recombination and maintain the
translational reading frame would be the 3' end of the luciferase gene.
Once this deleted genome had been made, there was a selective advantage
for this genome over the dicistronic genome. Most probably, a
combination of enhanced translation/replication and encapsidation
facilitated by the PV IRES contributed to the advantage of the
monocistronic over the dicistronic replicon. In support of this, we
found greater amplification in the encapsidation of monocistronic
PV-Luc compared with any other mono- or dicistronic replicons (Fig. 4).
An extension of this rationale could be applied to understanding
the genome stability of the dicistronic replicon EMCV-Luc-PV following serial passage. In this case, one deletion that might be
predicted for the dicistronic EMCV-Luc-PV would be removal of the
complete luciferase gene and EMCV IRES to form a smaller replicon
consisting of a complete PV 5'NTR fused with the remaining VP1 gene. If
this replicon occurred though, the overall genome size would be
approximately 70% of the wild-type PV genome. Previous studies
analyzing the lengths of PV defective interfering genomes have
reported that a genome 27% the size of PV could be encapsidated (5); smaller size genomes were not tested. We have
found that genomes 70% or smaller were not efficiently encapsidated
using our complementation system (W. S. Choi and C. D. Morrow, unpublished data). A second deleted genome which might occur
would result in the recombinant 5'NTR, including the first 108 nucleotides of the PV genome, and the EMCV IRES followed by the
luciferase gene fused to the VP1-P2-P3 region of the PV genome; this
replicon would have deleted the PV IRES. The overall gene structure of this replicon would be similar to that observed for the major deletion
product found following passage of the dicistronic PV-Luc-EMCV. To
determine why this replicon was not found, we compared the relative
encapsidation efficiency of a similar replicon EMCV-Luc with that of
the dicistronic replicon, EMCV-Luc-PV. We found that the dicistronic
replicon, EMCV-Luc-PV, was more efficiently amplified than EMCV-Luc
under identical experimental conditions. The dicistronic replicon then
would have a selective advantage in encapsidation compared with the
monocistronic EMCV-Luc replicon. Why the dicistronic replicon was
amplified more efficiently than the monocistronic containing the EMCV
IRES is not clear. Translation/replication of the monocistronic
EMCV-Luc was similar, if not greater, than that for the dicistronic
EMCV-Luc-PV replicon (Johansen and Morrow, unpublished). One
possibility is the poliovirus IRES plays a role in enhancing
encapsidation. In support of this idea, recent studies have suggested a
coupling of RNA replication/translation and encapsidation (23). Since the newly synthesized plus-strand PV genome RNA could either be translated or encapsidated, it is possible that the
interaction of viral proteins, possibly P1, with the IRES might be
involved in the switch from translation to encapsidation. Future
studies using the complementation system in combination with the
monocistronic and dicistronic replicons will allow the opportunity to
address this possibility.
 |
ACKNOWLEDGMENTS |
We thank Miroslav J. Novak for helpful discussions and Dee Martin
for preparation of the manuscript.
We thank Sylvia McPherson, UAB AIDS Center Molecular Biology
Core, for construction of dicistronic replicons (supported by grant
AI27767). The UAB AIDS Center Sequencing Core Facilities (AI27767) carried out DNA sequencing. L.K.J. was supported in part by training grant T32GM08111. This work was supported by grants
AI25005 and AI28147 to C.D.M.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, University of Alabama at Birmingham, Birmingham, AL
35294. Phone: (205) 934-5705. Fax: (205) 934-1580. E-mail:
casey_morrow{at}micro.microbio.uab.edu.
 |
REFERENCES |
| 1.
|
Alexander, L.,
H. H. Lu, and E. Wimmer.
1994.
Poliovirus containing picornavirus type 1 and/or type 2 internal ribosomal entry site elements: genetic hybrids and the expression of a foreign gene.
Proc. Natl. Acad. Sci. USA
91:1406-1410[Abstract/Free Full Text].
|
| 2.
|
Andino, R.,
E. Rieckhof,
P. L. Achacosp, and D. Baltimore.
1993.
Poliovirus RNA synthesis utilizes an RNP complex formed around the 5'-end of viral RNA.
EMBO J.
12:3587-3598[Medline].
|
| 3.
|
Ansardi, D. C.,
Z. Moldoveanu,
D. C. Porter,
D. E. Walker,
R. M. Conry,
A. F. LoBuglio,
S. McPherson, and C. D. Morrow.
1994.
Characterization of poliovirus replicons encoding carcinoembryonic antigens.
Cancer Res.
54:6359-6363[Abstract/Free Full Text].
|
| 4.
|
Ansardi, D. C.,
D. C. Porter, and C. D. Morrow.
1993.
Complementation of a poliovirus defective genome by a recombinant vaccinia virus which provides P1 capsid precursor in trans.
J. Virol.
67:3684-3690[Abstract/Free Full Text].
|
| 5.
|
Barclay, W.,
Q. Li,
G. Hutchinson,
D. Moon,
A. Richardson,
N. Percy,
J. W. Almond, and D. J. Evans.
1998.
Encapsidation studies of poliovirus subgenomic replicons.
J. Gen. Virol.
79:1725-1734[Abstract].
|
| 6.
|
Choi, W. S.,
R. Pal-Ghosh, and C. D. Morrow.
1991.
Expression of human immunodeficiency virus type 1 (HIV-1) Gag, Pol, and Env proteins from chimeric HIV-1-poliovirus minireplicons.
J. Virol.
65:2875-2883[Abstract/Free Full Text].
|
| 7.
|
Gromeier, M.,
L. Alexander, and E. Wimmer.
1996.
Internal ribosomal entry site substitution eliminates neurovirulence in intergeneic poliovirus recombinants.
Proc. Natl. Acad. Sci. USA
93:2370-2375[Abstract/Free Full Text].
|
| 8.
|
Harris, K. S.,
S. R. Reddigari,
J. H. Nicklin, and E. Wimmer.
1992.
Purification and characterization of poliovirus polypeptide 3CD, a proteinase and a precursor for RNA polymerase.
J. Virol.
66:7481-7489[Abstract/Free Full Text].
|
| 9.
|
Hellen, C. U. T.,
C. K. Lee, and E. Wimmer.
1992.
Determinants of substrate recognition by poliovirus 2A proteinase.
J. Virol.
66:3330-3338[Abstract/Free Full Text].
|
| 10.
|
Iizuka, N.,
M. Kohara,
K. Hagino-Yamagishi,
S. Abe, and T. Komatsu.
1989.
Construction of less neurovirulent polioviruses by introducing deletions into the 5' noncoding sequence of the genome.
J. Virol.
63:5354-5363[Abstract/Free Full Text].
|
| 11.
|
Jackson, R. J., and A. Kaminski.
1995.
Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond.
RNA
1:985-1000[Medline].
|
| 12.
|
Jang, S. K.,
M. V. Davies,
R. J. Kaufman, and E. Wimmer.
1989.
Initiation of protein synthesis by internal entry of ribosomes into the 5' nontranslated region of encephalomyocarditis virus RNA in vivo.
J. Virol.
63:1651-1660[Abstract/Free Full Text].
|
| 13.
|
Jang, S. K.,
H. G. Krausslich,
J. H. Nicklin,
G. M. Duke,
A. C. Palmenberg, and E. Wimmer.
1988.
A segment of the 5' nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation.
J. Virol.
62:2636-2643[Abstract/Free Full Text].
|
| 14.
|
Jang, S. K.,
T. V. Pestova,
C. U. T. Hellen,
G. W. Witherell, and E. Wimmer.
1990.
Cap-independent translations of picornavirus RNAs: structure and function of the internal ribosomal entry site.
Enzyme
44:292-309[Medline].
|
| 15.
| Johansen, L., and C. D. Morrow. The RNA
encompassing the internal ribosome entry site in the poliovirus 5'
non-translational region enhances the encapsidation of genomic RNA.
Virology, in press.
|
| 16.
|
Jore, J.,
B. Degues,
R. J. Jackson,
P. H. Pouwels, and B. E. Enger-Valk.
1988.
Poliovirus protein 3CD is the active protease for processing of the precursor protein P1 in vitro.
J. Gen. Virol.
69:1627-1636[Abstract/Free Full Text].
|
| 17.
|
Kirkegaard, K., and D. Baltimore.
1986.
The mechanism of RNA recombination in poliovirus.
Cell
47:433-443[CrossRef][Medline].
|
| 18.
|
Kitamura, N.,
B. L. Semler,
P. G. Rothberg,
G. R. Larsen,
C. J. Adler,
A. J. Dorner,
E. A. Emini,
R. Hanecak,
J. J. Lee,
S. van der Werf,
C. W. Anderson, and E. Wimmer.
1981.
Primary structure, gene organization and polypeptide expression of poliovirus RNA.
Nature
291:547-553[CrossRef][Medline].
|
| 19.
|
Kuge, S., and A. Nomoto.
1987.
Construction of a viable deletion and insertion mutants of the Sabin strain type 1 poliovirus: function of the 5' noncoding sequence in viral replication.
J. Virol.
61:1478-1487[Abstract/Free Full Text].
|
| 20.
|
Molla, A.,
S. Jang,
A. B. Paul,
Q. Reuer, and E. Wimmer.
1992.
Cardioviral internal ribosome entry site is functional in a genetically engineered dicistronic poliovirus.
Nature
356:255-257[CrossRef][Medline].
|
| 21.
|
Molla, A. A.,
V. Paul,
M. Schmid,
S. K. Jang, and E. Wimmer.
1993.
Studies on dicistronic poliovirus implicate viral proteinase 2Apro in RNA replication.
Virology
196:739-747[CrossRef][Medline].
|
| 22.
|
Nicholson, R.,
J. Pelletier,
S.-Y. Le, and N. Sonenberg.
1991.
Structural and functional analysis of the ribosome landing pad of poliovirus type 2: in vitro translation studies.
J. Virol.
63:5886-5894.
|
| 23.
|
Nugent, C. I.,
K. L. Johnson,
P. Sarnow, and K. Kirkegaard.
1999.
Functional coupling between replication and packaging of poliovirus replicon RNA.
J. Virol.
73:427-435[Abstract/Free Full Text].
|
| 24.
|
Paul, V.,
J. Mugavero,
A. A. Molla, and E. Wimmer.
1998.
Internal ribosomal entry site scanning of the poliovirus polyprotein: implications for proteolytic processing.
Virology
250:241-253[CrossRef][Medline].
|
| 25.
|
Pelletier, J.,
G. Kaplan,
V. R. Racaniello, and N. Sonenberg.
1988.
Cap-independent translation of poliovirus mRNA is conferred by sequence elements within the 5' noncoding region.
Mol. Cell. Biol.
8:1103-1112[Abstract/Free Full Text].
|
| 26.
|
Pelletier, J., and N. Sonenberg.
1989.
Internal binding of eukaryotic ribosomes on poliovirus RNA: translation in HeLa cell extracts.
J. Virol.
63:441-444[Abstract/Free Full Text].
|
| 27.
|
Pelletier, J., and N. Sonenberg.
1988.
Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA.
Nature
334:320-325[CrossRef][Medline].
|
| 28.
|
Porter, D. C.,
D. C. Ansardi,
W. S. Choi, and C. D. Morrow.
1993.
Encapsidation of genetically engineered poliovirus minireplicons which express human immunodeficiency virus type 1 Gag and Pol proteins upon infection.
J. Virol.
67:3712-3719[Abstract/Free Full Text].
|
| 29.
|
Porter, D. C.,
D. C. Ansardi,
J. Wang,
S. McPherson,
Z. Moldoveanu, and C. D. Morrow.
1998.
Demonstration of the specificity of poliovirus encapsidation using novel replicons which encode enzymatically active firefly luciferase.
Virology
243:1-11[CrossRef][Medline].
|
| 30.
|
Rueckert, R., and E. Wimmer.
1984.
Systematic nomenclature for picornavirus proteins.
J. Virol.
50:957-959[Abstract/Free Full Text].
|
| 31.
|
Semler, B. L.,
R. Hanecak,
C. W. Anderson, and E. Wimmer.
1981.
Cleavage sites in the polypeptide precursors of poliovirus protein P2-X.
Virology
114:589-594[CrossRef][Medline].
|
| 32.
|
Toyoda, H.,
M. J. H. Nicklin,
M. G. Murray,
C. W. Anderson,
J. J. Dunn,
F. W. Studier, and E. Wimmer.
1986.
A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein.
Cell
45:761-770[CrossRef][Medline].
|
| 33.
|
Wimmer, E.,
C. U. T. Hellen, and X. Cao.
1993.
Genetics of poliovirus.
Annu. Rev. Genet.
27:353-436[CrossRef][Medline].
|
| 34.
|
Ypma-Wong, M. F.,
P. G. Dewalt,
V. H. Johnson,
J. G. Lamb, and B. L. Semler.
1988.
Protein 3CD is the major poliovirus proteinase responsible for cleavage of the P1 capsid precursor.
Virology
166:265-270[CrossRef][Medline].
|
Journal of Virology, September 2000, p. 8335-8342, Vol. 74, No. 18
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Liu, Y., Franco, D., Paul, A. V., Wimmer, E.
(2007). Tyrosine 3 of Poliovirus Terminal Peptide VPg(3B) Has an Essential Function in RNA Replication in the Context of Its Precursor Protein, 3AB. J. Virol.
81: 5669-5684
[Abstract]
[Full Text]
-
Arita, M., Shimizu, H., Miyamura, T.
(2004). Characterization of in vitro and in vivo phenotypes of poliovirus type 1 mutants with reduced viral protein synthesis activity. J. Gen. Virol.
85: 1933-1944
[Abstract]
[Full Text]
-
Hirasawa, K., Kim, A., Han, H.-S., Han, J., Jun, H.-S., Yoon, J.-W.
(2003). Effect of p38 Mitogen-Activated Protein Kinase on the Replication of Encephalomyocarditis Virus. J. Virol.
77: 5649-5656
[Abstract]
[Full Text]
-
Vignuzzi, M., Gerbaud, S., van der Werf, S., Escriou, N.
(2002). Expression of a Membrane-Anchored Glycoprotein, the Influenza Virus Hemagglutinin, by Dicistronic Replicons Derived from the Poliovirus Genome. J. Virol.
76: 5285-5290
[Abstract]
[Full Text]
-
Martínez-Salas, E., Ramos, R., Lafuente, E., López de Quinto, S.
(2001). Functional interactions in internal translation initiation directed by viral and cellular IRES elements. J. Gen. Virol.
82: 973-984
[Full Text]